Program Death Ligan-1 (PD-L1) Expression in Invasif Breast Carcinoma of No Special Type

Authors

  • Astuti Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Upik A. Miskad Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Gunawan Arsyadi Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Andi A. Zainuddin Department of Public Health, Hasanuddin University, Makassar, Indonesia
  • Syarifuddin Wahid Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia
  • Berti J. Nelwan Department of Pathology Anatomy, Hasanuddin University, Makassar, Indonesia

Keywords:

invasive breast carcinoma, PD-L1, grade

Abstract

Breast carcinoma is the most frequently cancer in women (24%) and the main cause of cancer death in women worldwide. Based on data from globocan 2018 shows the incidence of breast cancer is around 2.08 million (11.6%) which is the second rank of all cancers after lung cancer with a mortality rate of 626.6 thousand (6.6%). However, prognosis of the breast carcinoma is influenced by several factors, including tumor histology grade and Tumor Infiltrating Lymphocytes (TILs). PD-L1 expression has been investigated as a potential biomarker and immune checkpoint to assess the response of various types of cancer. This study aims to determine PD-L1 expression in Invasive Breast Carcinoma of No Special Type (IBC-NST) grades 1,2 and 3. This study used a sample of 80 cases of paraffin block for IBC-NST patients from 2017 to 2020. There were 17 samples (21.3%) with grade 1, 32 samples (40%) with grade 2, and 31 samples (38.8%) with grade 3. The number of samples with positive PD-L1 expression were 63 samples, and 17 samples of negative PDL-1 expression were obtained. In the PD-L1 negative group, from a total of 17 samples, 4 samples were grade 1, 10 samples were grade 2, and 3 samples were grade 3. In the PD-L1 positive group, from a total of 63 samples, 13 samples with grade 1, 22 with grade 2, and 28 samples with grade 3. Based on the Chi-square test, p value = 0.115 (p > 0.05). The proportion of PD-L1 expression was higher at higher grades. There was no significant difference in PD-L1 expression in IBC-NST grade 1, grade 2 and grade 3.

References

. Rakha, E., Allison, K., Ellis, I., et al. (2019) ‘Invasive Breast Carcinoma: General Overview’, in Lokuhetty, D. et al. (eds) WHO Classification of Tumours Breast Tumours. 5th edn. France: International Agency for Pesearch on Cancer (lABC).

. Bray, F. et al. (2018) ‘Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, CA: A Cancer Journal for Clinicians, 68, pp. 394–424. doi: 10.3322/caac.21492.

. Kanker Payudara’ (2016) InfoDATIN. Jakarta: Pusat Data dan Informasi Kementrian Kesehatan RI, pp. 1–9.

. Collins, L. C. (2018) ‘Breast’, in Goldblum, J. R. et al. (eds) Rosai and Ackerman’s Surgical Pathology. 11th edn. Philadelphia: Elsevier, pp. 1434–1529.

. Kurozumi, S. et al. (2019) ‘Clinicopathological Values of PD-L1 Expression in HER2 positive Breast Cancer’, Scientific Reports. Springer US, 9(16662), pp. 1–8. doi: 10.1038/s41598-019-52944-6.

. Evangelou, Z. et al. (2020) ‘PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old’, In Vivo, 34(2), pp. 639–647. doi: 10.21873/invivo.11818.

. Guo, L., Lin, Y. and Kwok, H. F. (2017) ‘The Function and Regulation of PD-L1 in Immunotherapy’, ADMET & DMPK, 5(3), pp. 159–172. doi: 10.5599/admet.5.3.442.

. Karnik, T. et al. (2018) ‘PD-L1 in Breast Cancer : Comparative Analysis of 3 Different Antibodies’, Human Pathology, 72, pp. 28–34. doi: 10.1016/j.humpath.2017.08.010.

. Lakhani, S. (2012) WHO Classification of Tumours of The Breast. 4th edn. Edited by M. Lakhani, Sunil; Ellis, Ian; Schnitt, Stuart; Tan, Puay; van de Vijver. Lyon, France: International Agency for Research on Cancer. doi: 10.1017/CBO9781107415324.004.

. Ju, X. et al. (2020) ‘Regulation of PD-L1 Expression in Cancer and Clinical Implications in Immunotherapy’, American Journal of Cancer Research, 10(1), pp. 1–11.

. Dunn, G. P., Old, L. J. and Schreiber, R. D. (2004) ‘The Immunobiology of Cancer Immunosurveillance and Immunoediting’, Immunity, 21, pp. 137–148.

. Guan, J. et al. (2017) ‘Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade’, Archives of Pathology & Laboratory Medicine, 141(6), pp. 851–861. doi: 10.5858/arpa.2016-0361-RA.

. He, J. et al. (2018) ‘Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications’, American Journal of Clinical Pathology, 149(3), pp. 253–261. doi: 10.1093/ajcp/aqx162.

. Zhou, T. et al. (2018) ‘Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis’, Anti-Cancer Drugs, 29(9), pp. 904–910. doi: 10.1097/CAD.0000000000000683.

Downloads

Published

2022-02-05

How to Cite

Astuti, Upik A. Miskad, Gunawan Arsyadi, Andi A. Zainuddin, Syarifuddin Wahid, & Berti J. Nelwan. (2022). Program Death Ligan-1 (PD-L1) Expression in Invasif Breast Carcinoma of No Special Type. International Journal of Sciences: Basic and Applied Research (IJSBAR), 61(1), 331–337. Retrieved from https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/13637

Issue

Section

Articles